COMPANY RESEARCHIN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
Historical disclosure does not rule out subsequent financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| IN006 | RSV-A / RSV-B prefusion F antigens · Prevention of RSV infection | Phase 2 (IN006; company disclosure) | Refer to the program-specific stage source. This record does not include unverified cross-trial results or efficacy rankings. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.
Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
